Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.
The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.
Injections given every month or every other month were preferred over daily pills.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.